[CMRX] Chimerix, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.75 Change: 0.2 (4.4%)
Ext. hours: Change: 0 (0%)

chart CMRX

Refresh chart

Strongest Trends Summary For CMRX

CMRX is in the medium-term up 38% above S&P in 1 month. In the long-term down -35% below S&P in 1 year and down -51% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel, oral antivirals to address unmet medical needs in the United States. Its lead compounds include brincidofovir (CMX001), which is in Phase III clinical development; CMX157, a nucleotide analog that has completed Phase I study for the treatment of HIV infections. The company?s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has collaboration and license agreement with Merck Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 34.71% Sales Growth - Q/Q7.09% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-25.97% ROE-27.65% ROI
Current Ratio10.78 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin-1578.72% Net Profit Margin-1582.88% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities700 K Cash From Investing Activities-54.72 M Cash From Operating Activities-18.84 M Gross Profit
Net Profit-22.27 M Operating Profit-22.33 M Total Assets274.12 M Total Current Assets177.26 M
Total Current Liabilities16.44 M Total Debt2.89 M Total Liabilities16.6 M Total Revenue1.24 M
Technical Data
High 52 week4.9 Low 52 week1.79 Last close3.5 Last change-4.37%
RSI73.17 Average true range0.24 Beta1.18 Volume236.01 K
Simple moving average 20 days19.72% Simple moving average 50 days40.3% Simple moving average 200 days14.21%
Performance Data
Performance Week12.18% Performance Month34.1% Performance Quart75.88% Performance Half10.41%
Performance Year-27.98% Performance Year-to-date36.19% Volatility daily4.29% Volatility weekly9.6%
Volatility monthly19.66% Volatility yearly68.12% Relative Volume181.52% Average Volume591.99 K
New High New Low

News

2019-05-16 09:11:01 | Will Chimerix to Surge Higher?

2019-05-09 14:08:22 | Edited Transcript of CMRX earnings conference call or presentation 9-May-19 12:30pm GMT

2019-05-09 09:25:01 | Chimerix CMRX Reports Q1 Loss, Tops Revenue Estimates

2019-05-09 08:25:59 | Chimerix: 1Q Earnings Snapshot

2019-05-09 08:00:00 | Chimerix Announces First Quarter 2019 Financial Results and Strategy Update

2019-05-09 06:30:00 | Chimerix, Inc. to Host Earnings Call

2019-05-02 16:01:00 | Chimerix to Announce First Quarter 2019 Financial Results on May 9, 2019

2019-04-29 10:31:02 | Will Chimerix CMRX Report Negative Q1 Earnings? What You Should Know

2019-04-12 13:43:38 | One Thing To Remember About The Chimerix, Inc. NASDAQ:CMRX Share Price

2019-04-09 11:21:50 | Chimerix taps former Endocyte executive as new CEO

2019-04-09 08:10:29 | The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing

2019-04-08 17:00:00 | Chimerix Announces Management Updates

2019-04-05 14:14:57 | Again, Durham pharma loses a drug development partner

2019-03-07 12:24:00 | Should You Be Worried About Insider Transactions At Chimerix, Inc. NASDAQ:CMRX?

2019-03-05 16:09:29 | Edited Transcript of CMRX earnings conference call or presentation 5-Mar-19 1:30pm GMT

2019-03-05 07:00:00 | Chimerix Announces Fourth Quarter and Full Year 2018 Financial Results

2019-03-04 08:00:00 | Chimerix to Present at Cowen and Company 39th Annual Health Care Conference

2019-02-26 08:00:00 | Chimerix to Announce Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019

2019-02-22 08:00:00 | Chimerix Presents Results from Post-hoc Analysis of Phase 3 Study

2019-02-14 08:15:22 | Chimerix filing reveals ex-CEO's severance package after sudden resignation

2019-02-11 07:55:00 | New Research Coverage Highlights United Parcel Service, Healthcare Trust of America, CommVault, SPX FLOW, Chimerix, and International Speedway — Consolidated Revenues, Company Growth, and Expectations for 2019

2019-02-06 14:20:49 | Sudden Departure: Chimerix CEO, board member resigns

2019-02-06 08:00:00 | Chimerix Announces Management Transition

2019-01-30 11:51:55 | What Type Of Shareholder Owns Chimerix, Inc.’s NASDAQ:CMRX?

2019-01-24 10:17:03 | Will Overall Growth Aid Thermo Fisher's TMO Q4 Earnings?

2019-01-24 10:03:03 | Can Solid Consumables Drive Illumina's ILMN Q4 Earnings?

2019-01-18 06:36:11 | What Lies Ahead for Abbott ABT Stock This Earnings Season?

2019-01-17 09:38:02 | 4 Medical Product Stocks Likely to Top Q4 Earnings Estimates

2019-01-04 07:30:00 | Chimerix to Present at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-27 09:23:36 | Stocks down in December for pharma firms in the Triangle

2018-12-22 04:43:29 | Should You Avoid Chimerix Inc CMRX?

2018-12-18 08:35:01 | 5 Beaten-Down Medical Product Stocks to Rebound in 2019

2018-12-12 11:26:38 | Is Chimerix, Inc. NASDAQ:CMRX Overpaying Its CEO?

2018-12-03 07:55:00 | New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix — Factors of Influence, Major Initiatives and Sustained Production

2018-11-08 07:44:33 | Chimerix: 3Q Earnings Snapshot

2018-11-08 07:00:00 | Chimerix Announces Third Quarter 2018 Financial Results

2018-11-07 08:14:16 | Chimerix to Present at the Stifel 2018 Healthcare Conference

2018-11-05 14:29:22 | The most valuable public companies in the Triangle Slideshow

2018-11-01 08:00:00 | Chimerix to Announce Third Quarter 2018 Financial Results on November 8, 2018

2018-10-27 13:00:00 | Chimerix Presents Preclinical Data Demonstrating Antiviral Activity of Brincidofovir Against Polyomavirus at Kidney Week 2018

2018-10-24 07:25:00 | Report: Developing Opportunities within Univar, Aqua America, Chimerix, Superior Energy Services, TechTarget, and ZIOPHARM Oncology — Future Expectations, Projections Moving into 2018

2018-10-11 16:01:00 | Chimerix to Host Annual Investor Update on October 17, 2018

2018-10-11 13:23:06 | How Should You Think About Chimerix Inc’s NASDAQ:CMRX Risks?

2018-10-05 07:00:00 | Chimerix Presents Results from Multiple Ascending Dose Study of IV Brincidofovir at IDWeek

2018-10-04 07:00:00 | Landmark AdVance Study Shows Adenovirus Burden Correlates with Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

2018-09-26 07:30:00 | Chimerix to Present at Cantor Fitzgerald Global Healthcare Conference

2018-09-04 14:38:20 | Inside The List: Highest-Paid Public Company CEOs

2018-08-29 07:00:00 | Chimerix to Participate in September Investor Conferences

2018-08-28 07:30:00 | Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2018-08-08 09:50:01 | Chimerix CMRX Reports Q2 Loss, Tops Revenue Estimates